Mutual of America Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Mutual of America Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-193	Closed	-$290K	–	1261
2014 Q3	$290K	Buy	+193	New	+$279K	0.01%	1145
2013 Q4	–	Sell	-554	Closed	-$577K	–	1245
2013 Q3	$577K	Buy	554 +14	+3%	+$15K	0.02%	1061
2013 Q2	$591K	Buy	+540	New	+$602K	0.02%	1034

Other funds holding VIRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Mutual of America Capital Management's VIRX Position: Q4 2014 in Review

Mutual of America Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2014, closing a stake of 193 shares — an estimated $290K sold.

Mutual of America Capital Management first reported a position in VIRX in Q2 2013 and held it in 3 quarters. The position peaked at $591K in Q2 2013. 78 funds tracked by Wall St. Rank hold VIRX as of Q4 2014.

Mutual of America Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
Mutual of America Capital Management sold 193 Viracta Therapeutics, Inc. Common Stock shares in Q4 2014, an estimated $290K.
Mutual of America Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 3 quarters.
Mutual of America Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $591K in Q2 2013.
78 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2014.

Based on Mutual of America Capital Management's 13F filing for Q4 2014, filed 4 Feb 2015.